An observational study in Heart Failure, sponsored by Beckman Coulter, Inc.. Completed at 3 sites in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by Beckman Coulter, Inc. (part of Danaher Corporation) · Observational
The goal is to establish clinical performance of a BNP assay on the intended use population and establish clinical concordance on a separate device.
6,331 studies on the registry are indexed under Heart Failure; 1,396 are open to participants now.
This study's enrollment of 1,361 is above the median of 200 across 1,983 observational studies indexed under Heart Failure.
Browse Heart Failure studies →Beckman Coulter, Inc. is the lead sponsor of 31 studies on the registry; 1 is open to participants now.
First submitted after Beckman Coulter, Inc. became part of Danaher Corporation.
Counted across the registry records on this site, refreshed daily.
Specimens are to be collected under BNP-05-24 protocol are used. Approximately 1100 K2 EDTA samples with concentrations that span the analytical measuring range (AMR) are used in this testing study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Targeting subjects in the acute care setting that present with suspicion of either new onset or worsening symptoms of heart failure
Diagnostic Test: BNP
Blood collected during this study will be tested on separate IUO BNP assay on a separate protocol. No active interventions will occur during this study.
Number of participants with BNP value above clinical decision point
Subjects with BNP value above clinical decision point - Heart Failure Positive
Time frame: Through study completion, approximately 9 months
Number of participants with BNP value below clinical decision point
Subjects with BNP value below clinical decision point - Heart failure negative subjects
Time frame: Through study completion, approximately 9 months
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.